Genetic Test Can Identify Triple Negative Breast Cancer Treatment Responders

A test including 53 genes can predict who will respond and who will not respond to triple negative breast cancer immunotherapy.

DNA methylation markers predict recurrence-free interval in triple

Triple-negative breast cancer: challenges and opportunities of a

Triple-Negative Breast Cancer's Metastatic Drivers Revealed

Forecast: Liquid Biopsy Market to Exceed $18 Billion by 2032

Therapeutics Archives - Inside Precision Medicine

Current Oncology, Free Full-Text

Biomedicines, Free Full-Text

Breast Cancer Recurrence Screening Blood Test – Signatera

Cancers, Free Full-Text

Inside Precision Medicine on LinkedIn: Precision Immuno-Oncology